Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10916294 | Nuclear Medicine and Biology | 2005 | 13 Pages |
Abstract
The development of radioligands suitable for studying the central nervous system (CNS) norepinephrine transporter (NET) in vivo will provide important new tools for examining the pathophysiology and pharmacotherapy of a variety of neuropsychiatric disorders including major depression. Towards this end, a series of trans-3-phenyl-1-indanamine derivatives were prepared and evaluated in vitro. The biological properties of the most promising compound, [11C]3-BrPA, were investigated in rat biodistribution and nonhuman primate PET studies. Despite high in vitro affinity for the human NET, the uptake of [11C]3-BrPA in the brain and the heart was not displaceable with pharmacological doses of NET antagonists.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jonathan McConathy, Michael J. Owens, Clinton D. Kilts, Eugene J. Malveaux, John R. Votaw, Charles B. Nemeroff, Mark M. Goodman,